CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 
 

XFOR's Operating Income Growth by Quarter and Year

X4 Pharmaceuticals Inc's Operating Income results by quarter and year




XFOR Operating Income (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - -27.21 -20.15 -19.12
III Quarter September - -25.81 -20.57 -19.00
II Quarter June - -29.30 -21.27 -17.94
I Quarter March -37.29 -25.58 -29.06 -17.66
FY   -37.29 -107.90 -91.05 -73.72



XFOR Operating Income first quarter 2024 Y/Y Growth Comment
X4 Pharmaceuticals Inc in the first quarter 2024 recorded Operating Loss of $ -37.29 millions.

According to the results reported in the first quarter 2024, X4 Pharmaceuticals Inc achieved the best Operating Income growth in Biotechnology & Pharmaceuticals industry. While X4 Pharmaceuticals Inc' s Operating Income no change of % ranks overall at the positon no. in the first quarter 2024.

Explain Operating Income growth


XFOR Operating Income ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
X4 Pharmaceuticals Inc's first quarter 2024 Operating Income $ -37.29 millions XFOR's Income Statement
X4 Pharmaceuticals Inc's first quarter 2023 Operating Income $ -25.58 millions Quarterly XFOR's Income Statement
New: More XFOR's historic Operating Income Growth >>


XFOR Operating Income (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

X4 Pharmaceuticals Inc's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


XFOR's I. Quarter Q/Q Operating Income Comment
Current Operating Loss of -37.29 millions by X4 Pharmaceuticals Inc come out even worse considering the Operating Loss -27.21 millions in the fourth quarter.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential Operating Income growth. While X4 Pharmaceuticals Inc's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


XFOR's I. Quarter Q/Q Operating Income Comment
Recent results of -37.29 millions by X4 Pharmaceuticals Inc look even less good if you take a look at -27.21 millions in the previous quarter.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential Operating Income growth. While X4 Pharmaceuticals Inc's Operating Income growth quarter on quarter, overall rank is .


X4 Pharmaceuticals Inc's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Operating Income 12 Months Ending $ -119.61 $ -107.90 $ -100.84 $ -95.61 $ -87.57
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
X4 Pharmaceuticals Inc' has realized cumulative trailing twelve months Operating Loss of $ -120 millions in the Mar 31 2024 period.
The results are worsening as the cumulative Operating Loss is getting bigger from $ -107.9 millions in the twelve months ending a quarter before and $ -91.047 millions for the twelve months ending in the quarter Dec 31 2022 Allison Baker wrote.

X4 Pharmaceuticals Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
X4 Pharmaceuticals Inc' has realized cumulative trailing twelve months Operating Loss of $ -120 millions in the Mar 31 2024 period.
The results are detiriorating as the cumulative Operating Loss is becoming larger from $ -107.9 millions in TTM ending quarter Sep 30 2023 and $ -91.047 millions for the twelve months ending in the quarter a year ago.

X4 Pharmaceuticals Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Biotechnology & Pharmaceuticals Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
XFOR's Operating Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for XFOR's Competitors
Operating Income Growth for X4 Pharmaceuticals Inc's Suppliers
Operating Income Growth for XFOR's Customers

You may also want to know
XFOR's Annual Growth Rates XFOR's Profitability Ratios XFOR's Asset Turnover Ratio XFOR's Dividend Growth
XFOR's Roe XFOR's Valuation Ratios XFOR's Financial Strength Ratios XFOR's Dividend Payout Ratio
XFOR's Roa XFOR's Inventory Turnover Ratio XFOR's Growth Rates XFOR's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Mar 31 2024
Halozyme Therapeutics Inc 77.58%$ 77.581 millions
Eli Lilly And Company75.33%$ 75.335 millions
Radnet Inc 69.97%$ 69.975 millions
Surgery Partners Inc 63.79%$ 63.793 millions
Bausch Health Companies Inc 60.57%$ 60.571 millions
Carlisle Companies Incorporated59.72%$ 59.716 millions
Sotera Health Company59.37%$ 59.366 millions
National Healthcare Corp56.10%$ 56.103 millions
Davita Inc 55.26%$ 55.255 millions
Electromed Inc 53.93%$ 53.930 millions
Avanos Medical Inc 53.85%$ 53.846 millions
Penumbra Inc51.11%$ 51.111 millions
Lemaitre Vascular Inc 50.80%$ 50.800 millions
Merck and Co Inc 50.76%$ 50.762 millions
Biomarin Pharmaceutical Inc49.06%$ 49.059 millions
Vertex Pharmaceuticals Inc46.28%$ 46.277 millions
Dariohealth Corp 43.90%$ 43.899 millions
Amphastar Pharmaceuticals Inc 43.60%$ 43.601 millions
Innovative Eyewear Inc 39.94%$ 39.942 millions
Merit Medical Systems Inc36.16%$ 36.156 millions
Stryker Corp32.24%$ 32.245 millions
Harmony Biosciences Holdings inc 28.72%$ 28.721 millions
Select Medical Holdings Corp28.07%$ 28.067 millions
Essa Pharma inc 27.76%$ 27.759 millions
United Therapeutics Corporation25.28%$ 25.281 millions
Resmed Inc 24.58%$ 24.583 millions
Ufp Technologies Inc 24.01%$ 24.009 millions
Progyny Inc 23.40%$ 23.396 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com